CLARINEX (desloratadine) · Merck
CLARINEX is a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older.
Details
- Status
- Prescription
- First Approved
- 2001-12-21
- Routes
- ORAL, Oral
- Dosage Forms
- TABLET, SOLUTION, TABLET, ORALLY DISINTEGRATING, SYRUP, Tablet
CLARINEX Approval History
What CLARINEX Treats
4 FDA approvalsOriginally approved for its first indication in 2001 . Covers 4 distinct patient populations.
- Other (4)
Merck's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07566351 | MDP.26.03.216 | Ph 2 | recruiting | Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis |
| NCT07486583 | MD-142-2025 | Ph 3 | not yet recruiting | Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. |
| NCT07333716 UC | 12/2025 TRop1 | Ph 2 | recruiting | Desloratadine in Patients With Ulcerative Colitis |
| NCT05214911 DESPRED | EF177 | Ph 3 | completed | Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children |
| NCT06916884 DESCUBRA | SIL-30810-III-23(1) | Ph 3 | recruiting | Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine |
| NCT01916967 results posted | 4117-201 132243 | Ph 3 | completed | An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) |
| NCT02646020 EGFR-TKIs | TAPE001 | Ph 2 | completed | Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment |
| NCT02507635 | 535 | Ph 4 | completed | Anti-inflammatory H1 Antihistamines Allergic Rhinitis |
| NCT01985789 | PHPY2013/14 | Ph 4 | completed | Anti-histamines and Methacholine Challenges. |
| NCT01400828 | YCD159 | Ph 3 | completed | Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis |
| NCT01940393 | GACE-01 | Ph 4 | completed | Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria |
| NCT01444196 AECUDATT | 2008-005746-22 2008-005746-22 | Ph 4 | completed | Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CLARINEX FDA Label Details
Indications & Usage
FDA Label (PDF)CLARINEX is a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older. 1.1 Seasonal Allergic Rhinitis CLARINEX ® is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and ol...
Track CLARINEX with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.